Who is sponsoring LISPAP?

LISPAP is sponsored by Chiesi Farmaceutici S.p.A..

What condition does LISPAP study?

LISPAP studies Respiratory Distress Syndrome (RDS).

What drugs are being tested in LISPAP?

Interventions: LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube).

What is the status of LISPAP?

LISPAP is currently TERMINATED.

Last reviewed 2023-11-07 · How we verify

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration (LISPAP)

NCT02772081 PHASE3 TERMINATED Results posted

This study compared the administration of porcine surfactant (poractant alfa, Curosurf®) through a less invasive method (LISA), using a thin catheter, CHF 6440 (LISACATH®), during non-invasive ventilation (CPAP, NIPPV, BiPAP) with an approved conventional surfactant administration during invasive ventilation followed by rapid extubation in terms of short term and mid-term safety and efficacy in spontaneously breathing preterm neonates who have clinical signs of respiratory distress syndrome (RDS).

Details

Lead sponsor	Chiesi Farmaceutici S.p.A.
Phase	PHASE3
Status	TERMINATED
Enrolment	33
Start date	Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Aug 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Respiratory Distress Syndrome (RDS)

Interventions

LISA combination product (Curosurf+catheter CHF6440)
Curosurf through conventional administration (endotracheal tube)

Countries

United States